In an open-label, multicenter trial involving 233 patients with Marfan syndrome randomly assigned to receive either losartan or no further treatment, losartan was associated with a significantly reduced rate of aortic root dilatation over approximately 3 years (0.77 ± 1.36 mm vs 1.35 ± 1.55 mm in controls; P = 0.014). No losartan-associated differences were observed for dilatation of the ascending aorta, aortic arch, or descending aorta in the overall study population. Aortic volume did not significantly differ between the two treatment groups, nor did rates of prophylactic aortic root surgery, distal aortic surgical intervention, type B aortic dissection, or cardiovascular death (the last of which occurred in no patients).
References
Groenink, M. et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur. Heart J. 10.1093/eurheartj/eht334
Rights and permissions
About this article
Cite this article
Aortic root dilatation reduced with losartan use in patients with Marfan syndrome. Nat Rev Cardiol 10, 617 (2013). https://doi.org/10.1038/nrcardio.2013.144
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2013.144